GlassScriptPhysician profile
Manojkumar A Dobariya
NPI 1164717401
$2,538.90
in general payments reported to CMS, 2019-2025
28 companies · $56.36 in 2025
The $56.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $558 · 2021: $366 · 2022: $158 · 2023: $183 · 2024: $484 · 2025: $56.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $302.69 | 2019-2021 | |
| Smith+Nephew, INC. | $239.21 | 2020 | |
| Kerecis Limited | $189.34 | 2021 | |
| Novo Nordisk INC | $183.77 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Kci USA, INC. | $144.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $138.05 | 2019-2023 | |
| Amarin Pharma, INC. | $134.18 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.45 | 2019-2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $125.40 | 2019 | |
| Cleerly, INC. | $112.68 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Abbott Laboratories | $112.59 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $94.05 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $81.51 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $71.23 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.24 | 2019-2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $52.82 | 2019 | |
| Merck Sharp & Dohme LLC | $52.23 | 2023 | Recarbrio, Dificid, Zerbaxa |
| Cequr Corporation | $47.01 | 2024 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $46.21 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $41.83 | 2019-2023 | Myrbetriq |
| Lilly USA, LLC | $31.15 | 2022-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $29.92 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $26.84 | 2019-2020 | |
| Kyowa Kirin, INC. | $21.78 | 2024 | Crysvita |
| Dexcom, INC. | $20.15 | 2022 | |
| Biogen, INC. | $16.91 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.22 | 2022 | |
| Pfizer INC. | $13.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manojkumar Dobariya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.